Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Update

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 474,300 shares, a decrease of 14.6% from the November 30th total of 555,600 shares. Based on an average trading volume of 660,100 shares, the short-interest ratio is currently 0.7 days. Currently, 23.7% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Aegis reiterated a “buy” rating and issued a $15.00 target price on shares of Sunshine Biopharma in a research note on Thursday, December 5th.

Sunshine Biopharma Stock Performance

Sunshine Biopharma stock traded down $0.01 during midday trading on Friday, hitting $3.06. 56,616 shares of the company’s stock were exchanged, compared to its average volume of 265,924. The company has a market cap of $3.75 million, a P/E ratio of -0.02 and a beta of 1.42. The stock has a 50-day moving average price of $2.81 and a two-hundred day moving average price of $2.14. Sunshine Biopharma has a 52-week low of $2.11 and a 52-week high of $599.80.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of $9.00 by ($9.94). The firm had revenue of $8.44 million for the quarter. Sunshine Biopharma had a negative return on equity of 17.89% and a negative net margin of 12.82%.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.